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Fibroblasts derived from 
oesophageal adenocarcinoma differ 
in DNA methylation profile from 
normal oesophageal fibroblasts
Eric Smith  1,2, Helen M. Palethorpe1, Annette L. Hayden3, Joanne P. Young1,2, 
 Timothy J. Underwood  3 & Paul A. Drew1,4
Oesophageal adenocarcinoma (OAC) is increasing in incidence and has a poor prognosis. Tumour 
derived fibroblasts (TDFs) differ functionally from normal fibroblasts (NDFs), and play a pivotal role 
in cancer. Many of the differences persist through subculture. We measured the DNA methylation 
profiles of 10 TDFs from OAC with 12 NDF from normal oesophageal mucosa using Infinium 
HumanMethylation450 Beadchips and found they differed in multidimensional scaling analysis. We 
identified 4,856 differentially methylated CpGs (DMCs, adjusted p < 0.01 and absolute difference in 
average β-value > 0.15), of which 3,243 (66.8%) were hypomethylated in TDFs compared to NDFs. 
Hypermethylated DMCs were enriched at transcription start sites (TSSs) and in CpG islands, and 
depleted in transcriptional enhancers. Gene ontology analysis of genes with DMCs at TSSs revealed 
an enrichment of genes involved in development, morphogenesis, migration, adhesion, regulation 
of processes and response to stimuli. Alpha-smooth muscle actin (α-SMA) is a marker of activated 
fibroblasts and a poor prognostic indicator in OAC. Hypomethylated DMCs were observed at the TSS of 
transcript variant 2 of α-SMA, which correlated with an increase in α-SMA protein expression. These 
data suggest that DNA methylation may contribute to the maintenance of the TDF phenotype.
Oesophageal adenocarcinoma (OAC), which has increased rapidly in incidence in the Western world over recent 
decades1, has a five year survival rate of about 15%2. Most patients are unsuitable for treatment with curative 
intent. The major risk factors include gastro-oesophageal reflux disease and obesity, which lead to the premalig-
nant condition, Barrett’s oesophagus, the only described precursor lesion for OAC. A deeper understanding of the 
mechanisms that regulate the development and progression of OAC may lead to improvements in early diagnosis 
and treatment.
An emerging body of evidence demonstrates that fibroblasts play a significant role in the development and 
progression of solid tumours (reviewed in ref. 3). Within a cancer they are a phenotypically heterogeneous pop-
ulation of cells, distinct from the fibroblasts found in normal tissue, and are referred to as activated, cancer asso-
ciated, or tumour derived fibroblasts (reviewed in ref. 4). These have been shown to promote tumour growth, 
facilitate tumour cell invasion, migration and metastasis, promote therapeutic drug resistance and act to prevent 
immune cell infiltration. Expression signatures that characterise these fibroblasts are associated with poor sur-
vival outcomes in many solid tumour types including OAC5–10.
A number of studies have reported that many of the phenotypic characteristics of tumour derived fibroblasts 
(TDFs) are maintained in culture11, 12. This is consistent with at least some of the phenotypic alterations being 
maintained by epigenetic mechanisms such as DNA methylation13–15, which involves the covalent addition of 
a methyl group to, most commonly, the cytosine residue of a cytosine-phosphate-guanine (CpG) dinucleotide. 
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Regions of the genome with a relatively high density of CpGs, CpG islands, and their flanking shores and shelves 
are associated with 60–70% of all human genes16. Methylation at the transcription start site (TSS) or within the 
body of genes is frequently associated with the silencing of transcription, and methylation of transcriptional 
enhancers may also affect gene transcription17. Aberrant methylation in intergenic regions has been associated 
with genomic instability or global silencing of large chromatin domains. Whilst genome-wide DNA methylation 
profiles of many tumour types, including OAC18–22, have been ascertained, these studies have been conducted 
using whole tissue samples or cancer cell lines. There are reports of the genome-wide DNA methylation profiles 
of TDFs in breast13, gastric23, colorectal14, and non-small cell lung carcinoma15, but none in OAC.
The aim of this study was to compare the genome-wide DNA methylation profiles of low-passage primary 
TDFs from patients with OAC to fibroblasts derived from macroscopically normal oesophageal squamous 
mucosa. We show that the TDFs have a DNA methylation profile which distinguishes them from most NDFs. 
Differentially methylated CpGs were observed at TSSs of genes which have a known role in cancer develop-
ment and progression, suggesting that the TDF phenotype may be regulated, at least in part, by epigenetic 
mechanisms.
Results
Tumour derived fibroblasts were aberrantly methylated. Twenty-two primary fibroblast lines were 
established from resected specimens of 16 patients with oesophageal cancer (Supplementary Table S1). There 
were 10 TDFs and 12 NDFs, which included six patient matched fibroblast pairs. The median age of the patients 
was 65 years (range 57 to 82). There was not a significant difference in the age of the patients from whom the 
TDFs and NDFs were established. There were 13 males and three females. Five patients were treated with surgery 
alone, and 11 received a combination of neoadjuvant chemotherapy and surgery.
The genome-wide DNA methylation profile of the fibroblasts was measured using the Infinium 
HumanMethylation450 Beadchip. Unsupervised pairwise multidimensional scaling was performed using the 
β-values for all 408,329 probes included in the analysis (Fig. 1a). The distribution of the TDFs differed from 
NDFs. The NDFs formed a tight cluster, with two outliers. In contrast, the TDFs were more widely dispersed. 
The coefficient of variation (CV) for the median β-values of each fibroblast was 7.6% for the NDFs and 10.2% 
for the TDFs, but the variance of median β-values of each fibroblast was not significantly different (p = 0.1836). 
Comparing methylation in the TDFs and NDFs, there were 4,856 DMCs, of which 3,243 (66.8%) were hypo-
methylated and 1,613 (33.2%) hypermethylated. Hierarchical clustering of these 4,856 DMCs revealed that the 
fibroblasts formed two major clusters, with 10 of the 12 NDF clustering together, the remaining two NDF (N.181 
and N.217) within the TDF cluster (Fig. 1b).
Differentially methylated CpGs and functional genomic regions. We analysed the distribution of 
the DMCs between the functional genomic regions. The probes were allocated as TSS1500, TSS200, 5′UTR, 1st 
exon, gene body or 3′UTR according to the Illumina probe annotation24. Many probes are annotated to more 
than one genomic region since a locus may be within more than one gene, or more than one variant of a gene, so 
that the sum of the loci in genomic locations is greater than the number of probes analysed. Probes which were 
not annotated to a gene region were categorised as intergenic. The results in Table 1 show the proportion of all 
CpGs analysed and DMCs in each of these regions. There was a significant difference in the distribution of the 
DMCs across the functional genomic locations compared to that of all the cytosines analysed (Chi square test 
for proportions: p < 0.0001). The most significant differences were a depletion around the TSS, particularly the 
TSS200 (3.6% of DMCs compared to 11.6% of all analysed) and the first exon (2.2% v 7.2%), and an enrichment 
in the intergenic region (32.0% v 19.5%). Overall there were significantly fewer differentially methylated cytosines 
associated with the promoter region (defined as TSS1500, TSS200, 5′UTR and 1st Exon; 27.9% versus 46.1%). 
There were no significant differences in the distribution of DMCs within the annotated microRNAs or lncRNAs. 
The proportion of hypomethylated and hypermethylated DMCs differed between the gene regions (Table 2). 
Hypermethylated DMCs were more frequent in the TSS200 and 3′UTR, and less in the gene body and intergenic 
regions.
Differentially methylated CpGs and CpG islands. CpG islands are important genomic regulatory ele-
ments that are defined by a high density of CpGs relative to entire genome. The regions 2 kilobases either side 
of an island are defined as shores, the 2 kilobase regions flanking the shores are defined as shelves24, and here 
we define the remainder of the genome as open seas. The distribution of DMCs in the context of CpG islands is 
shown in Table 1. Of all the CpGs for analysis, 65.7% were in islands, shores or shelves, compared to 44.3% of the 
DMCs. Within the CpG islands DMCs were significantly depleted (9.3% v 32.7% of all analysed cytosines), but 
there was no significant difference in the distribution of DMCs in the shores or shelves. There was a significantly 
greater proportion of DMCs in the open seas (55.7% v 34.3%). There was significant enrichment of hypermethyl-
ated DMCs in CpG islands and adjacent shores, and depletion in shelves and open seas (Table 2).
We then determined if there were a difference in the distribution of DMCs between CpG islands that overlap 
annotated genes and those located in the intergenic regions. An island was classified as intragenic if any of its 
CpGs were in an annotated gene region (that is, within the TSS1500 to 3′UTR regions). Of the DMCs within CpG 
islands, a significantly greater proportion were in islands in the intergenic regions (34.2% v 13.8% of all CpGs, 
odds ratio (OR) 3.276, 95% confidence interval (CI) 2.696–3.981, p < 0.0001), and lesser in islands which over-
lapped genes (31.8% v 70.0%, p < 0.0001). The proportion of hypermethylated DMCs within CpG islands did not 
significantly vary between intergenic and intragenic CpG islands (62.1% and 54.8% respectively, OR 1.389, 95% 
CI 0.9096–1.998, p = 0.1647).
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Differentially methylated CpGs and enhancer regions. Next, we investigated the distribution of 
DMCs between enhancer and non-enhancer regions. Of the total of 408,329 CpGs for analysis, 90,996 (22.3%) 
were in enhancer regions. The DMCs were significantly enriched in enhancer (46.3% of DMCs compared to 
22.3% of all analysed, p < 0.0001) compared to non-enhancer regions (53.7% v 77.7%) (Table 1). The propor-
tion of hypermethylated DMCs was significantly lower in enhancer compared to non-enhancer regions (Table 2; 
p < 0.0001). Further analysis of the DMCs in enhancers revealed that they were enriched in the intergenic com-
pared to intragenic regions (57.9% versus 40.1% respectively, OR 2.058, 95% CI 1.825–2.320, p < 0.0001). The 
proportion of hypermethylated DMCs in enhancers was greater in those in intragenic compared to intergenic 
regions (31.9% and 23.7% respectively, OR 1.507, 95% CI 1.248–1.919, p < 0.0001). The proportion of hypermeth-
ylated DMCs in non-enhancer regions was greater in the intragenic compared to intergenic regions (39.1% and 
32.9% respectively, OR 1.310, 95% CI 1.093–1.570, p = 0.0040).
Methylation of ACTA2 correlated with decreased α-SMA protein expression. To ascertain the 
potential functional significance of the observed DMC, we conducted gene ontology enrichment analyses using 
genes that had one or more DMCs located within 1,500 bases of their TSS. Of the 4,856 DMCs, 1,354 (27.9%) 
were located within 1,500 bases of a TSS, representing 1,145 unique Entrez Gene IDs. Of these, 743 (64.9%) 
were hypomethylated in TDFs, and 402 (35.1%) were hypermethylated. Hypermethylated DMCs were observed 
Figure 1. Genome-wide DNA methylation profiles of TDFs and NDFs. (a) Multidimensional scaling 
performed using the β-values for all 408,329 probes for NDFs (blue triangles) and TDFs (red circles). (b) 
Hierarchical clustering using the 4,856 DMC for NDFs (blue) and TDFs (red).
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about the TSS of genes predominantly involved in development, morphogenesis and migration, whilst genes with 
hypomethylated DMCs were involved in regulation of processes, response to stimuli, development and adhesion 
(Supplementary Table S2).
A gene which featured in several enriched biological processes was ACTA2. Multiple alternatively spliced vari-
ants of ACTA2 have been reported, and they each encode the same protein, alpha-smooth muscle actin (α-SMA). 
Variant 2 varies from the other variants by an alternate TSS (Fig. 2a). We observed that the region about the 
TSS for transcript variant 2 was hypomethylated in TDFs compared to NDFs (Fig. 2a and b). In contrast, the 
β-values for the probes about the TSS of variant 1 and 3 varied little between TDFs and NDFs, and were relatively 
low (β-value < 0.15). Sufficient material was available from three patient matched fibroblast pairs to analyse the 
expression of α-SMA by western immunoblot. The results confirmed that α-SMA was elevated in these TDFs 
compared to the NDFs (Fig. 2c and d). Methylation about the TSS of variant 2, but not variant 1 and 3, inversely 
correlated with α-SMA protein expression (Fig. 2e), suggesting that the low α-SMA expression observed in cul-
tured oesophageal NDFs was associated with DNA methylation about the TSS of variant 2.
Discussion
This is the first study to compare the genome-wide DNA methylation profiles of oesophageal NDFs to OAC 
TDFs using the high resolution Infinium HumanMethylation450 BeadChip. Multidimensional scaling analysis 
of all probes analysed showed that, with respect to DNA methylation, the NDFs clustered tightly apart from two 
outliers, whereas the TDFs were markedly heterogeneous. Hierarchical clustering using the 4,856 DMCs demon-
strated that the TDFs grouped differently to the NDFs. Detailed examination of the genomic locations of the 
DMCs revealed significant regional variation in DNA methylation between the two fibroblast groups. In TDFs, 
the DMCs were depleted about the transcription start sites and in CpG islands and enriched in gene bodies, 
open seas and in enhancers. The DMCs were observed in the TSSs of genes which have a known role in cancer 
development and progression. Methylation was significantly decreased at the TSS of variant 2 of α-SMA, which 
correlated with an increase in α-SMA protein expression.
Previous studies have investigated DNA methylation profiles of TDFs in breast13, gastric23, colorectal14, and 
non-small cell lung carcinoma15. Consistent with our findings, these studies demonstrated differences in DNA 
methylation between TDF and NDFs, with general DNA hypomethylation and concomitant focal hypermethyla-
tion observed in TDFs compared to NDFs. Only one used the Infinium HumanMethylation450 BeadChip15, and 
reported a strikingly similar distribution of DMCs across the functional genomic regions, including the depletion 
about TSSs and CpG islands, and the enrichment in gene bodies and open seas. In addition, we report the novel 
observation of differential methylation in transcriptional enhancers. Multiple enhancers may cooperate to finely 
tune the expression of a single transcript, and integrate extracellular signals with intracellular cell fate informa-
tion to generate cell type-specific transcriptional responses25. Together, these results suggest that differences in 
DNA methylation, through their role in regulation of gene expression, contribute to the alterations in fibroblast 
phenotypes observed in cancer.
The results from the multidimensional scaling of all CpGs analysed and the hierarchical clustering of DMCs 
showed that the DNA methylation profiles of the TDFs were markedly more heterogeneous than the NDFs. The 
primary function of fibroblasts is to establish, maintain, and modify connective tissue26. They are a heterogeneous 
DMC (%) All CpGs Analysed (%) OR (95% CI) p-value
Gene Regions
Totala 5,302 479,691
TSS1500 682 (12.9%) 73,530 (15.3%) 0.8137 (0.7505–0.8822) <0.0001
TSS200 192 (3.6%) 55,640 (11.6%) 0.2839 (0.2457–0.3280) <0.0001
5′UTR 488 (9.2%) 57,408 (12.0%) 0.7435 (0.6771–0.8164) <0.0001
1st Exon 117 (2.2%) 34,391 (7.2%) 0.2898 (0.2415–0.3482) <0.0001
Gene body 1,954 (36.9%) 148,809 (31.0%) 1.302 (1.231–1.377) <0.0001
3′UTR 173 (3.3%) 16,571 (3.5%) 0.9421 (0.8089–1.097) 0.4652
Intragenic 1,686 (32.0%) 93,342 (19.5%) 1.947 (1.837–2.064) <0.0001
microRNA 33 (0.6%) 2,331 (0.5%) 0.9995 (0.7114–1.404) >0.999
lncRNA 4 (0.08%) 429 (0.01%) 0.658 (0.2562–1.675) 0.5835
CpG Island Regions
Total 4,856 408,329
CGI 453 (9.3%) 133,415 (32.7%) 0.2093 (0.1900–0.2306) <0.0001
Shores 1,208 (24.9%) 97,243 (23.8%) 1.060 (0.9929–1.132) 0.0836
Shelves 488 (10.0%) 37,691 (9.2%) 1.100 (1.001–1.209) 0.0502
Open sea 2,707 (55.7%) 139,980 (34.3%) 2.443 (2.307–2.586) <0.0001
Enhancer Regions
Non-enhancer 2,608 (53.7%) 317,333 (77.7%)
Enhancer 2,248 (46.3%) 90,996 (22.3%) 3.057 (2.888–3.246) <0.0001
Table 1. The proportion of all CpGs analysed and differentially methylated cytosines (DMC) in each annotated 
region. aProbes may annotate to more than one gene region.
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population of cells, particularly in disease. The origin of TDFs can be from resident fibroblasts, as well as infiltrat-
ing cells, including epithelial, endothelial, and bone marrow-derived mesenchymal stem cells27 and fibrocytes15, 
28. They can exist in differing states of activation and functional potential29–31. It is therefore highly likely that 
primary cultures of TDFs contain differing proportions of fibroblast subpopulations. The heterogeneity of their 
DNA methylation profiles most likely reflects the heterogeneity of their origins and functions in cancer.
Expression of α-SMA is commonly used as a marker for TDFs, and is associated with poor prognosis in a 
range of cancers, including OAC10, 31, oesophageal squamous cell carcinoma32, colorectal6, breast33, and head and 
neck cancers34. In humans, the α-SMA protein is encoded by the ACTA2 gene, and transcript variant 2 varies 
from 1 and 3 by an alternate TSS, with the entire first exon of each variant being a 5′UTR. We observed the novel 
finding that DNA methylation about the TSS of variant 2 inversely correlated with α-SMA protein expression. 
This raises the possibility that methylation of this region may be of functional significance in repressing α-SMA 
expression in oesophageal fibroblasts. In rat lung fibroblasts, myofibroblasts, and alveolar epithelial type cells, 
methylation of the ACTA2 promoter inversely correlated with expression35. In addition, inhibition of DNMT 
activity led to significant induction of α-SMA expression, while ectopic expression of DNMTs suppressed its 
expression, suggesting that DNA methylation plays a key role in the regulation of α-SMA gene expression during 
myofibroblast differentiation35. Further experiments confirming the functional significance of the observed meth-
ylation are warranted, considering the prognostic significance of α-SMA expression.
It is possible that neoadjuvant chemotherapy might have altered the DNA methylation profiles in either of the 
normal or cancer associated fibroblasts. To the best of our knowledge, there are no studies that demonstrate this 
in fibroblasts, although several reports suggest that this may occur in cancer cells36, 37. Future studies to compare 
the DNA methylation of fibroblasts before and after chemotherapy would require the harvesting of sufficient 
fibroblasts from the small amount of tissue obtainable by biopsy.
In conclusion, we compared the genome-wide DNA methylation profiles of 10 TDFs from oesophageal ade-
nocarcinoma tumour tissues with 12 NDFs from macroscopically normal oesophageal mucosa using Infinium 
HumanMethylation450 Beadchips. The genome-wide DNA methylation profile of TDFs differed significantly 
from that of NDFs. The focal distribution of the DMCs about the transcription start sites and within CpG islands 
and transcriptional enhancers may, by the regulation of gene expression, contribute to the establishment and 
maintenance of the TDF phenotype in vitro and in vivo.
Methods
Research Ethics. All methods were carried out in accordance with relevant guidelines and regulations.
All experimental protocols were approved by the Southampton and South West Hampshire Research Ethics 
Committee (09/H0504/66). Informed consent was obtained from all subjects.
Primary human oesophageal fibroblasts. Primary human oesophageal fibroblast lines were established 
as described previously38. Briefly, macroscopically normal squamous mucosa and tumour tissues were sampled 
from resection specimens and transported in Hank’s balanced salt solution (Invitrogen, Carlsbad, CA, USA). 
Tissues were washed twice in Dulbecco’s phosphate buffered saline (DPBS; Invitrogen), placed in fresh DPBS 
supplemented with 250 ng/ml amphotericin B (Invitrogen), and diced into 2 mm3 pieces. Single fragments of 
tissue were then placed into individual wells of six-well plates, and cultured at 37 °C in a humidified atmosphere 
with 10% CO2. The fibroblast culture medium was composed of Dulbecco’s modified Eagle’s medium (Invitrogen) 
supplemented with 10% (v/v) fetal bovine serum (Autogen Bioclear UK Ltd, Wiltshire, UK or Sigma-Aldrich, 
St Louis, MO, USA), 100 units/ml penicillin, 100 μg/ml streptomycin, 250 ng/ml amphotericin B and 292 μg/ml 
Hypermethylated (%) Hypomethylated (%) Total OR (95% CI) p-value
Total 1,613 (33.2%) 3,243 (66.8%) 4,856
Gene Regions
TSS1500 237 (34.8%) 445 (65.2%) 682 1.083 (0.9133–1.284) 0.3823
TSS200 86 (44.8%) 106 (55.2%) 192 16.78 (13.59–20.72) <0.0001
5′UTR 166 (34.0%) 322 (66.0%) 488 1.041 (0.8540–1.268) 0.7302
1st Exon 39 (33.3%) 78 (66.7%) 117 1.005 (0.6813–1.484) 0.9424
Gene body 705 (36.1%) 1,249 (63.9%) 1,954 0.7294 (0.6510–0.8173) <0.0001
3′UTR 77 (44.5%) 96 (55.5%) 173 1.643 (1.210–2.232) 0.0018
Intragenic 468 (27.6%) 1,228 (72.4%) 1,696 0.6707 (0.5896–0.7629) <0.0001
CpG Island Regions
CGI 270 (59.6%) 183 (40.3%) 453 1.954 (1.790–2.134) <0.0001
Shores 489 (40.5%) 719 (59.5%) 1,208 1.314 (1.208–1.429) <0.0001
Shelves 138 (28.3%) 350 (71.7%) 488 0.8374 (0.7227–0.9703) <0.0001
Open sea 716 (26.4%) 1,991 (73.6%) 2,707 0.6337 (0.5848–0.6866) <0.0001
Enhancer Regions
Non-enhancer 976 (37.4%) 1,632 (62.6%) 2,608
Enhancer 637 (28.3%) 1,611 (71.7%) 2,248 0.6612 (0.5856–0.7464) <0.0001
Table 2. The percentage of hypermethylated or hypomethylated differentially methylated cytosines (DMC) in 
each or the annotated region.
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Figure 2. DNA methylation and expression of α-SMA (ACTA2). (a) The relative location of ACTA2 splice 
variants, individual β-values for all NDFs (blue circles) and TDFs (pink circles), and CpG islands. The lines 
for the β-values represent the average β-value for the NDF and TDF groups. (b) The β-values for all individual 
NDF and TDF samples for the probes cg03221266 and cg10894512 located at positions −152 bp or +102 bp 
respectively of the TSS of ACTA2 variant 2. *Benjamini-Hochberg adjusted p = 8.55 × 10−9, **Benjamini-
Hochberg adjusted p = 2.46 × 10−19. (c) Western immunoblot for α-SMA and the loading control HSC-70 for 
the three available patient matched pairs of NDFs (N.251, N.217 and N.108) and TDFs (T.251, T.217 and T.108). 
(d) Quantification of α-SMA protein expression for the three patient matched pairs. (e) Correlation between 
α-SMA protein expression and β-values for the probes about ACTA2 TSS of the splice variants for the three 
patient matched pairs.
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L-glutamine (Invitrogen). The primary fibroblasts were expanded by subculturing in fibroblast medium, on tissue 
culture treated plastic, at 37 °C in a humidified atmosphere with 5% CO2. The phenotype of ex-vivo fibroblasts 
was confirmed as vimentin-positive, cytokeratin-negative, CD31-negative and desmin-negative, as described 
previously38.
Genome-wide DNA methylation profiling. Genomic DNA was isolated from the primary fibroblasts at 
the earliest subculture that sufficient cells were available. The DNA was isolated using either the DNeasy Blood 
and Tissue Kit (Qiagen, Hilden, Germany) or Trizol (Invitrogen), and concentrated, if required, using the phenol 
chloroform ethanol precipitation method. The DNA (500–2000 ng) was bisulphite modified with the EZ DNA 
Methylation-Gold Kit (Zymo Research, Irvine, CA, USA), as described previously39, 40. The bisulphite-modified 
DNA was hybridized onto Infinium HumanMethylation450 BeadChips following the Illumina Infinium HD 
Methylation protocol, and scanned using an Illumina HiScan SQ scanner (Illumina, San Diego, CA, USA), as 
described previously41.
Raw fluorescence intensity values were normalised using the GenomeStudio Methylation Module (v1.8.5; 
Illumina), with background subtraction and normalisation to internal controls. Normalised intensities were used 
to calculate β-values. The β-value represents the percentage of the cytosines at that locus which were methylated, 
and ranges from 0 (no methylation) to 1 (complete methylation). The average β-value at each locus was calculated 
for the NDF and TDF groups.
Probes were excluded from the analysis if they did not target a cytosine within a CpG, or if they were known 
to align to a single nucleotide polymorphism (SNP) or to multiple locations42, or if its target cytosine was two 
or fewer nucleotides from a known SNP for which the SNP had a minor allele frequency above 0.0543, or if the 
detection p value, which defines the chance that the target signal was not distinguishable from background, was 
greater than 0.01 in any sample, or if the bead count was less than three. Probes on the X and Y chromosomes 
were also excluded.
Differentially methylated CpGs (DMCs) between the TDF and NDF groups were determined using the 
Illumina Custom Model in the GenomeStudio Methylation Module with false discovery rate (FDR) adjustment. 
The software calculates a p value for the significance of the difference in β-values between the groups for each 
locus, corrected for multiple testing using the Benjamini-Hochberg FDR adjustment. A CpG was considered 
to be differentially methylated if p < 0.01 and the absolute difference in the average β-values of each group was 
>0.15. A DMC was defined to be hypermethylated if the average β-value for the TDFs was greater than the 
NDFs, and hypomethylated if the average β-value for the TDFs was less than the NDFs. The allocation of DMCs 
into gene regions, CpG islands, and enhancer regions was determined from the Illumina GenomeStudio probe 
annotation24.
Gene ontology enrichment analysis of differentially methylated CpGs. The DMCs were aligned 
to the TSS of the nearest transcript using the FDb. Infinium Methylation. hg 19 annotation package (v2.2.0) in 
R (v3.3.0). Transcripts with one or more DMCs located within 1,500 bases up- or down-stream of its TSS were 
selected. The transcripts were converted to Entrez Gene IDs, and gene ontology enrichment analysis on all, hypo-
methylated, and hypermethylated DMC was performed using the clusterProfiler R package (v2.4.3)44.
Western immunoblot for alpha-smooth muscle actin (α-SMA). Measurement of specific protein 
expression by western immunoblots was performed as previously described10. Briefly, adherent fibroblasts were 
washed with DPBS, detached by trypsin digestion and pelleted by centrifugation. Pelleted cells were lysed with 
50 μl RIPA buffer (0.75 M NaCl, 5% NP40, 2.5% deoxycholic acid, 0.5% SDS, 0.25 M Tris, pH 8.0) for 15 minutes 
at 4 °C, and clarified by centrifugation at 8000 × g for 5 min. Protein was quantified by Bradford protein assay, and 
20 μg was resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to Hybond-ECL 
membranes (GE Healthcare Life Sciences, Buckinghamshire, UK). Membranes were immunostained using 
mouse monoclonal anti-α-SMA (M085129-2, Dako) and mouse monoclonal anti-HSC-70 (sc-7298, Santa Cruz, 
USA). Immunoreactivity was detected using horseradish peroxidase-labelled secondary antibody, and visualised 
with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific Pierce, Waltham, MA, USA) using 
a ChemiDoc-It Imager (UVP, Upland, CA, USA). The intensity of the α-SMA and the HSC-70 bands were deter-
mined using ImageJ (v1.47). The α-SMA expression was calculated as the ratio of the intensity of α-SMA divided 
by the intensity of HSC-70.
Statistical analysis. Pairwise multidimensional scaling was conducted using the LIMMA R package 
(v3.18.5). The equality of the fibroblast group variances was compared using the median centred Levene test 
in the car R package (v2.1-2). The proportion of DMCs in gene regions, CpG islands, or enhancer regions and 
the proportion of hypomethylated and hypermethylated DMC in each of these regions was analysed with the 
Chi-squared test with Yates correction, using Prism 6.0 h for Macintosh (GraphPad Software, San Diego, CA, 
USA). A two-tailed p < 0.05 was considered statistically significant.
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